BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 33573337)

  • 1. HPV Meets APOBEC: New Players in Head and Neck Cancer.
    Riva G; Albano C; Gugliesi F; Pasquero S; Pacheco SFC; Pecorari G; Landolfo S; Biolatti M; Dell'Oste V
    Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33573337
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distinct immune evasion in APOBEC-enriched, HPV-negative HNSCC.
    Messerschmidt C; Obermayer B; Klinghammer K; Ochsenreither S; Treue D; Stenzinger A; Glimm H; Fröhling S; Kindler T; Brandts CH; Schulze-Osthoff K; Weichert W; Tinhofer I; Klauschen F; Keilholz U; Beule D; Rieke DT
    Int J Cancer; 2020 Oct; 147(8):2293-2302. PubMed ID: 32468570
    [TBL] [Abstract][Full Text] [Related]  

  • 3. APOBEC Mutagenesis Is Concordant between Tumor and Viral Genomes in HPV-Positive Head and Neck Squamous Cell Carcinoma.
    Faden DL; Kuhs KAL; Lin M; Langenbucher A; Pinheiro M; Yeager M; Cullen M; Boland JF; Steinberg M; Bass S; Lewis JS; Lawrence MS; Ferris RL; Mirabello L
    Viruses; 2021 Aug; 13(8):. PubMed ID: 34452530
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PYHIN genes as potential biomarkers for prognosis of human papillomavirus-positive or -negative head and neck squamous cell carcinomas.
    Riva G; Pecorari G; Biolatti M; Pautasso S; Lo Cigno I; Garzaro M; Dell'Oste V; Landolfo S
    Mol Biol Rep; 2019 Jun; 46(3):3333-3347. PubMed ID: 30980272
    [TBL] [Abstract][Full Text] [Related]  

  • 5. APOBEC mutagenesis is tightly linked to the immune landscape and immunotherapy biomarkers in head and neck squamous cell carcinoma.
    Faden DL; Ding F; Lin Y; Zhai S; Kuo F; Chan TA; Morris LG; Ferris RL
    Oral Oncol; 2019 Sep; 96():140-147. PubMed ID: 31422205
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy Advances in Locally Advanced and Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Its Relationship With Human Papillomavirus.
    Wang H; Zhao Q; Zhang Y; Zhang Q; Zheng Z; Liu S; Liu Z; Meng L; Xin Y; Jiang X
    Front Immunol; 2021; 12():652054. PubMed ID: 34305889
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characteristics of B lymphocyte infiltration in HPV
    Zhang S; Wang B; Ma F; Tong F; Yan B; Liu T; Xie H; Song L; Yu S; Wei L
    Cancer Sci; 2021 Apr; 112(4):1402-1416. PubMed ID: 33529452
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HPV33+ HNSCC is associated with poor prognosis and has unique genomic and immunologic landscapes.
    Chatfield-Reed K; Gui S; O'Neill WQ; Teknos TN; Pan Q
    Oral Oncol; 2020 Jan; 100():104488. PubMed ID: 31835137
    [TBL] [Abstract][Full Text] [Related]  

  • 9. APOBEC3: Friend or Foe in Human Papillomavirus Infection and Oncogenesis?
    Warren CJ; Santiago ML; Pyeon D
    Annu Rev Virol; 2022 Sep; 9(1):375-395. PubMed ID: 35671565
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multi-modality analysis supports APOBEC as a major source of mutations in head and neck squamous cell carcinoma.
    Faden DL; Thomas S; Cantalupo PG; Agrawal N; Myers J; DeRisi J
    Oral Oncol; 2017 Nov; 74():8-14. PubMed ID: 29103756
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Programmed Death-1/Programmed Death-Ligand 1-Axis Blockade in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Stratified by Human Papillomavirus Status: A Systematic Review and Meta-Analysis.
    Xu Y; Zhu G; Maroun CA; Wu IXY; Huang D; Seiwert TY; Liu Y; Mandal R; Zhang X
    Front Immunol; 2021; 12():645170. PubMed ID: 33897693
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of the tumor immune microenvironment in human papillomavirus-positive and -negative head and neck squamous cell carcinomas.
    Succaria F; Kvistborg P; Stein JE; Engle EL; McMiller TL; Rooper LM; Thompson E; Berger AE; van den Brekel M; Zuur CL; Haanen J; Topalian SL; Taube JM
    Cancer Immunol Immunother; 2021 May; 70(5):1227-1237. PubMed ID: 33125511
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Somatic Host Cell Alterations in HPV Carcinogenesis.
    Litwin TR; Clarke MA; Dean M; Wentzensen N
    Viruses; 2017 Aug; 9(8):. PubMed ID: 28771191
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma cell marker, immunoglobulin J polypeptide, predicts early disease-specific mortality in HPV+ HNSCC.
    Gui S; O'Neill WQ; Teknos TN; Pan Q
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33737336
    [TBL] [Abstract][Full Text] [Related]  

  • 15. APOBEC-mediated genomic alterations link immunity and viral infection during human papillomavirus-driven cervical carcinogenesis.
    Chen L; Qiu X; Zhang N; Wang Y; Wang M; Li D; Wang L; Du Y
    Biosci Trends; 2017 Sep; 11(4):383-388. PubMed ID: 28717061
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HPV-positive status associated with inflamed immune microenvironment and improved response to anti-PD-1 therapy in head and neck squamous cell carcinoma.
    Wang J; Sun H; Zeng Q; Guo XJ; Wang H; Liu HH; Dong ZY
    Sci Rep; 2019 Sep; 9(1):13404. PubMed ID: 31527697
    [TBL] [Abstract][Full Text] [Related]  

  • 17. APOBEC-mediated cytosine deamination links PIK3CA helical domain mutations to human papillomavirus-driven tumor development.
    Henderson S; Chakravarthy A; Su X; Boshoff C; Fenton TR
    Cell Rep; 2014 Jun; 7(6):1833-41. PubMed ID: 24910434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EGFR overexpression increases radiotherapy response in HPV-positive head and neck cancer through inhibition of DNA damage repair and HPV E6 downregulation.
    Alsahafi EN; Thavaraj S; Sarvestani N; Novoplansky O; Elkabets M; Ayaz B; Tavassoli M; Legends MF
    Cancer Lett; 2021 Feb; 498():80-97. PubMed ID: 33137407
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Cao CH; Liu R; Lin XR; Luo JQ; Cao LJ; Zhang QJ; Lin SR; Geng L; Sun ZY; Ye SK; Yu ZY; Shi Y; Xia X
    Int J Biol Sci; 2021; 17(7):1744-1756. PubMed ID: 33994859
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patterns of antibody responses to nonviral cancer antigens in head and neck squamous cell carcinoma patients differ by human papillomavirus status.
    Gangkofner DS; Holzinger D; Schroeder L; Eichmüller SB; Zörnig I; Jäger D; Wichmann G; Dietz A; Broglie MA; Herold-Mende C; Dyckhoff G; Boscolo-Rizzo P; Ezic J; Marienfeld RB; Möller P; Völkel G; Kraus JM; Kestler HA; Brunner C; Schuler PJ; Wigand M; Theodoraki MN; Doescher J; Hoffmann TK; Pawlita M; Butt J; Waterboer T; Laban S
    Int J Cancer; 2019 Dec; 145(12):3436-3444. PubMed ID: 31407331
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.